A randomised trial of high dose therapy and autologous bone marrow transplantation versus continuing conventional combination chemotherapy for adults with lymphoblastic lymphoma

Not Applicable

Completed

• Conditions: ymphoma (non-Hodgkin's) cancer; Cancer; Lymphoma (non-Hodgkin's)

• Registration Number: ISRCTN58831878
• Lead Sponsor: Cancer Research UK (CRUK) (UK)

Brief Summary

2001 results in: ncbi.nlm.nih.gov/pubmed/11387366 (added 28/11/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 1997-04-30
• Study Start: 2001-07-01
• Last Update Posted: 6 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 119

Inclusion Criteria

1. Histologically documented lymphoblastic lymphoma
2. No prior chemotherapy or radiotherapy, except chemotherapy given for immediate relief of symptoms at presentation
3. Age 15 or over
4. All stages
5. No circulating blasts
6. Normal values for renal and hepatic function, unless directly attributable to lymphoma
7. Normal cardiac function
8. No evidence of Human Immunodeficiency Virus (HIV) infection

Exclusion Criteria

Patients will be excluded if they have HLA-identical siblings who are undergoing allogenic bone marrow transplantation. These patients should be registered with the trials office but will not be randomised.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ot provided at time of registration

Secondary Outcome Measures

Name	Time	Method
ot provided at time of registration